BioSpace News Archive

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial of IO-202, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with advanced solid tumors (NCT05309187).

CytoRecovery, Inc., a leader in the marker free enrichment, sorting, and recovery of live cells, presented recent study results at the American Association for Cancer Research (AACR) Annual Meeting 2022 currently being held in New Orleans.

Increasing prevalence of infectious diseases and genetic disorders across the globe, rapid advancements in genomic sequencing techniques, and rising number of genomic research based activities are some key factors expected to drive global market growth.

Increasing research in biotechnology and pharmaceutical sector, rising global prevalence of infectious and chronic diseases, and rapid advancements in protein therapeutics are some key factors expected to drive market revenue growth.

Entrinsic Bioscience and its licensee Nuvara Therapeutics announces they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting.

Aziyo Biologics, Inc. announced that the Company’s CanGaroo® Envelope will be highlighted in an upcoming Key Opinion Leader Call hosted by Cowen.

Navidea Biopharmaceuticals, Inc. announced that its Board of Directors has adopted a Section 382 Rights Agreement that is designed to protect the availability of the Company’s net operating loss carryforwards and other tax assets.

Computed axial tomography (CAT), prevalently known as computed tomography (CT), has differentiated applications in the medical care industry.

The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five Forces analysis, and competitive landscape.